Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer

A. Lipton, S. Scialla, H. Harvey, R. Dixon, R. Gordon, R. Hamilton, H. Ramsey, M. Weltz, R. Heckard, D. White

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Sixty-six patients with Duke's B 2 or C colon or rectal cancer were randomized for treatment with aspirin (ASA), 600 mg, p.o., twice daily x 2 years or placebo (P). Compliance was checked in both groups by random measurement of blood salicylate levels. Fifty-seven patients are currently evaluable. No difference in disease-free (p=.66) or overall survival (p=.90) is present between ASA and P groups. The time at which ASA therapy is started (within 2 or within 4 weeks) following surgery does not affect these results. Aspirin at conventional dosage is ineffective in preventing the appearance of metastases in patients with colo-rectal cancer.

Original languageEnglish (US)
Pages (from-to)419-429
Number of pages11
JournalJournal of Medicine
Issue number5-6
StatePublished - 1982

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer'. Together they form a unique fingerprint.

Cite this